Tag Archive for: ISA

ISA Completes Enrolment in Randomized Double Blind Phase 2 Clinical Trial of ISA101b in HPV16 induced Oropharyngeal Cancer

Study designed to investigate the efficacy and safety of ISA101b added to checkpoint inhibitor therapy in Human Papilloma Virus type 16 (HPV16) induced oropharyngeal cancer (OPC). Trial is part of an extensive clinical development program for ISA101b in a collaboration with Regeneron. Top line interim results anticipated in third quarter of 2023. Oegstgeest, 30 November […]

First-in-Human Study: Amplivant® Adjuvant Boosts Immune Response of Synthetic Long Peptide Immunotherapy

First-in-human study investigating the safety and immunogenicity of ISA’s proprietary Amplivant adjuvant conjugated to human papillomavirus type 16 (HPV16) Synthetic Long Peptides (SLPs). SLPs conjugated to Amplivant elicit a significant, strong immune response and dose related systemic T cell immunity when injected intradermally. Study demonstrates that SLPs conjugated to Amplivant have highly favourable tolerability and […]

ISA Pharmaceuticals’ Chief Scientific Officer Prof. Dr. Melief Awarded Fellowship at the Society for Immunotherapy of Cancer

Recognition of commendable, longstanding dedication to the field of cancer immunotherapy Oegstgeest, 15 July 2022 – ISA is delighted to announce that our Chief Scientific Officer (CSO) and Founder, Professor Dr. Cornelis “Kees” Melief has been nominated and selected by the Board of Directors of the Society for Immunotherapy of Cancer (SITC) as a Fellow of the Academy of […]

ISA Pharmaceuticals B.V. receives EUR 20m loan from European Investment Bank

The European Investment Bank and ISA Pharmaceuticals have signed a EUR 20 million loan agreement to support the development of ISA’s therapy for cancers caused by the Human Papillomavirus type 16 (HPV16). Read more